These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31689837)

  • 1. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report.
    Oda Y; Sato S; Kanbe E; Kamata W; Okada S; Tamai Y
    Medicine (Baltimore); 2019 Nov; 98(44):e17766. PubMed ID: 31689837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast phase of essential thrombocythemia: A single center study.
    Passamonti F; Rumi E; Arcaini L; Elena C; Castagnola C; Zappasodi P; Bernasconi P; Pietra D; Pascutto C; Cazzola M; Lazzarino M
    Am J Hematol; 2009 Oct; 84(10):641-4. PubMed ID: 19691103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
    Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
    Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation.
    Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
    J Thromb Thrombolysis; 2018 Jan; 45(1):106-113. PubMed ID: 29022213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
    Lambert JR; Gale RE; Linch DC
    Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
    Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
    Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
    Falanga A; Marchetti M; Vignoli A; Balducci D; Russo L; Guerini V; Barbui T
    Exp Hematol; 2007 May; 35(5):702-11. PubMed ID: 17577920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
    Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
    Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
    Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
    APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From prednisone to pylori: a case of Helicobacter pylori-induced chronic immune thrombocytopenia.
    Hill LJ; Tung EE
    BMJ Case Rep; 2014 Jul; 2014():. PubMed ID: 25035453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mean Platelet Volume and Platelet Distribution Width Indicate that Platelets Remain Small for Most of Their Lifespans in Patients with Essential Thrombocythemia.
    Lee E; Kim M; Jeon K; Lee J; Lee JS; Kim HS; Kang HJ; Lee YK
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.